BridgeBio Pharma announces an investor webinar on achondroplasia featuring Dr. Janet Legare on January 9, 2026.
Quiver AI Summary
BridgeBio Pharma, Inc. announced an investor webinar scheduled for January 9, 2026, at 8:00 am ET, featuring Dr. Janet Legare from the University of Wisconsin. Dr. Legare will discuss achondroplasia, its pathophysiology, and the need for new treatments, particularly focusing on infigratinib, currently being evaluated in the Phase 3 PROPEL 3 study for children with this condition. The webinar will also include updates from BridgeBio's skeletal dysplasia program team on the ongoing clinical development of infigratinib, with topline results anticipated in Q1 2026. Interested parties can access the live webcast through BridgeBio's investor page, with a replay available for 30 days post-event.
Potential Positives
- Announcement of an upcoming investor webinar featuring Dr. Janet Legare, a noted expert in the field, highlights the company's commitment to transparency and engagement with the investment community.
- Focus on the Phase 3 PROPEL 3 study of infigratinib for treating children with achondroplasia emphasizes the company's dedication to addressing significant unmet medical needs in genetic diseases.
- Topline results for the ongoing clinical study expected in Q1 2026 could provide important updates on the company’s pipeline and potential market opportunities, fostering investor confidence.
Potential Negatives
- None
FAQ
What is the purpose of the BridgeBio investor webinar?
The webinar will provide insights into achondroplasia and discuss the treatment infigratinib, part of clinical development efforts.
Who will be presenting at the investor webinar?
Dr. Janet Legare, a professor and expert in genetics and metabolism, will present at the event.
When is the BridgeBio investor webinar scheduled?
The investor webinar is scheduled for Friday, January 9, 2026, at 8:00 am ET.
How can I access the webinar?
You can access the live webcast on the “Events & Presentations” page of the BridgeBio website.
What topics will be covered in the investor webinar?
The webinar will cover achondroplasia, its pathophysiology, unmet needs, and the infigratinib development program.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 79 times in the past 6 months. Of those trades, 0 have been purchases and 79 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 53 sales selling 482,323 shares for an estimated $28,356,866.
- FRANK MCCORMICK has made 0 purchases and 7 sales selling 274,000 shares for an estimated $17,246,736.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 5 sales selling 76,524 shares for an estimated $4,087,207.
- RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
- HANNAH VALANTINE sold 25,484 shares for an estimated $1,683,727
- ANDREA ELLIS sold 17,167 shares for an estimated $841,183
- RANDAL W. SCOTT has made 0 purchases and 2 sales selling 10,000 shares for an estimated $666,465.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 3,000 shares for an estimated $193,960.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/22, 08/08 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BBIO Hedge Fund Activity
We have seen 217 institutional investors add shares of $BBIO stock to their portfolio, and 169 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIKING GLOBAL INVESTORS LP removed 2,577,526 shares (-13.9%) from their portfolio in Q3 2025, for an estimated $133,876,700
- CAPITAL RESEARCH GLOBAL INVESTORS removed 2,055,172 shares (-51.5%) from their portfolio in Q3 2025, for an estimated $106,745,633
- WOODLINE PARTNERS LP removed 1,506,482 shares (-88.4%) from their portfolio in Q3 2025, for an estimated $78,246,675
- HOOD RIVER CAPITAL MANAGEMENT LLC added 1,243,545 shares (+inf%) to their portfolio in Q3 2025, for an estimated $64,589,727
- INVESCO LTD. added 1,127,592 shares (+40.3%) to their portfolio in Q3 2025, for an estimated $58,567,128
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,051,679 shares (+inf%) to their portfolio in Q3 2025, for an estimated $54,624,207
- POLAR CAPITAL HOLDINGS PLC added 981,058 shares (+inf%) to their portfolio in Q3 2025, for an estimated $50,956,152
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Goldman Sachs issued a "Buy" rating on 10/31/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/30/2025
- Piper Sandler issued a "Overweight" rating on 10/30/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
- Truist Securities issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 16 analysts offer price targets for $BBIO in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Mani Foroohar from Leerink Partners set a target price of $86.0 on 12/15/2025
- William Pickering from Bernstein set a target price of $94.0 on 12/11/2025
- Derek Archila from Wells Fargo set a target price of $84.0 on 11/11/2025
- Anupam Rama from JP Morgan set a target price of $77.0 on 11/07/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $90.0 on 11/03/2025
- Paul Choi from Goldman Sachs set a target price of $100.0 on 10/31/2025
- Biren Amin from Piper Sandler set a target price of $98.0 on 10/30/2025
Full Release
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.
Dr. Legare will provide an overview of achondroplasia, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating infigratinib as a treatment for skeletal dysplasia, including achondroplasia. Dr. Legare actively engages with leading professional organizations, including the American Academy of Pediatrics, the Society for Pediatric Research, the American College of Medical Genetics, Little People of America, and the International Skeletal Dysplasia Society, and holds an affiliate appointment in the Department of Neurological Surgery. Her clinical expertise spans the diagnosis, management, and long-term care of children with skeletal dysplasia.
In addition to Dr. Legare, executive members of the skeletal dysplasia program team will review the ongoing infigratinib clinical development program and discuss the ongoing Phase 3 PROPEL 3 study, for which topline results are expected in Q1 2026.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit
bridgebio.com
and follow us on
LinkedIn
,
X
,
Facebook
,
Instagram
, and
YouTube
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]
